British researchers have found that 71 percent of patients with relapsing-remitting multiple sclerosis (MS) who were treated with the experimental drug alemtuzumab in a recent study showed no disease activity after four years. This figure is twice the percentage of patients who achieve remission for this period of time who take the standard treatment Rebif, the scientists say.
Read moreHi everybody! Hope you are all doing well. Just had a mammogram today. Just because you have MS doesn't mean you can't have other... Read more »
Multiple Sclerosis is a disease with no known cause. However, a runaway train can sometimes be safely returned to its station, never to... Read more »
Managing multiple sclerosis (MS) by therapy may essentially be divided into three areas of focus: treating the acute relapse, managing... Read more »
We have discussed differences between men and women who develop multiple sclerosis. Next we explored how hormones, specifically... Read more »
SECONDARY SEXUAL DYSFUNCTION IN MEN AND WOMEN WITH MS In multiple sclerosis, the incidence of fatigue, muscle tightness or spasms,... Read more »
Therapy for multiple sclerosis doesn't only mean medications made by pharmaceutical companies, but also physical and occupational therapy, cognitive... Read more »
This is a study to determine the safety and effectiveness of different doses of Cymbalta (duloxetine) compared to a placebo in reducing pain in... Read more »
Source: Harvard Decision Guide
When To Call A Professional Call your doctor immediately if you have symptoms of multiple sclerosis. Prognosis A minority of those with multiple... Read more »
Scientists at UT Southwestern Medical Center say a quick, painless eye measurement is showing promise as a way to diagnose multiple sclerosis (MS)... Read more »
The months or years of mystery have been solved. In many ways, you feel relief at having been given the diagnosis at last. MS...multiple... Read more »